The number and frequency of intravesical instillations for non-muscle-invasive bladder cancer (NMIBC) impairs quality of life and needs to be reported in clinical trials.

BioVaxys Technology Corp. (CSE: BIOV) (FSE: 5LB0) (OTCQB: BVAXF) ("BioVaxys" or the "Company"), a clinical stage biotechnology company focused on developing advanced treatments in oncology, infectious ...

PIVOT-006 Phase 3 topline data evaluating cretostimogene monotherapy for intermediate-risk NMIBC now expected in 1H 2026, nearly one year ahead ...

For individuals facing fear, uncertainty and repeated procedures associated with recurrent low-grade intermediate-risk bladder tumors, timely access to treatment can be critical. ZUSDURI, the first ...

RARITAN, N.J., July 17, 2025 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced that the U.S. Food and Drug Administration (FDA) granted Priority Review to the New Drug Application (NDA) ...

Impact of tumor burden or focality in recurrent low-grade intermediate-risk non-muscle-invasive bladder cancer on response to treatment with UGN-102: A substudy of the phase 3 ENVISION trial.

LAS VEGAS -- Patients with high-risk, treatment-unresponsive non-muscle invasive bladder cancer (NMIBC) had an unprecedented response rate and disease-free survival (DFS) with an investigational ...

Relmada Therapeutics, Inc. announced the presentation of an abstract at the American Urology Association (AUA2025) conference in Las Vegas, highlighting a study on NDV-01, an investigational therapy ...

Protara Therapeutics announced promising results from its Phase 2 ADVANCED-2 trial for TARA-002, an investigational therapy for high-risk non-muscle invasive bladder cancer (NMIBC). The study shows a ...

Detailed price information for Cg Oncology Inc (CGON-Q) from The Globe and Mail including charting and trades.

New research presented at the 2025 International Kidney Cancer Symposium found that patients with localized renal cell ...